ArticleNeuroImage. Clinical2025
Modulating the sense of agency in functional neurological disorder using real-time fMRI neurofeedback: a proof-of-concept study.
Article in NeuroImage. Clinical, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Functional Neurological Disorder: Neurobiological Mechanisms, Biomarkers, and Integrated Treatment in a Female-Predominant Neuropsychiatric Condition.Neurology international · 2026Review
- Working Memory as a Candidate Mechanism Linking Aging and the Sense of Agency: A Narrative Review.Brain sciences · 2026Review
- Functional and Structural Brain Imaging Correlates of Treatment Response in Functional Movement Disorder.Current neurology and neuroscience reports · 2026Review
- Relationships between brain functional connectivity and resting cardiac autonomic profiles in functional neurological disorder: A pilot study.NeuroImage. Clinical · 2026Article
- Brain imaging research is thriving in functional neurological disorder.NeuroImage. Clinical · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDisrupted sense of agency (SoA), the perceived loss of control over one's actions, is common in functional neurological disorder (FND) and linked to abnormal activation in agency-related networks, particularly the right temporoparietal junction (rTPJ). This proof-of-concept study tested whether fMRI neurofeedback (NF) could enhance SoA in FND by targeting the rTPJ.
methodsIn this single-arm feasibility study, 18 patients with mixed FND symptoms completed three NF trainings during an adaptive visuomotor task, receiving intermittent visual feedback of their rTPJ activity. Pre- and post-training assessments included subjective agency ratings, neuroimaging during a transfer task, and clinical evaluations.
resultsGroup-level subjective agency significantly increased after training (p = 0.0083), driven by responders (n = 8) who exhibited rTPJ (p = 0.042) and supplementary motor area (SMA) upregulation (p = 0.015) in the first session, alongside consistent task engagement. Behavioral gains coincided with trend-level decreases in rTPJ-dorsolateral prefrontal cortex (dlPFC) connectivity (p = 0.098), while non-responders showed reduced rTPJ-SMA connectivity (p = 0.008). No group-level clinical improvements were observed, but higher initial rTPJ (p = 0.03, ρ = -0.78) and dlPFC (p = 0.03, ρ = -0.75) activation were negatively associated with changes in self-reported core symptoms.
conclusionNF from rTPJ activity is feasible in FND and may enhance explicit SoA in a subset of patients through early neural modulation and sustained engagement. High inter-individual variability underscores the need for sham-controlled trials with optimized, engaging feedback designs and longitudinal monitoring to identify patients who could benefit from NF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.